Clinical Trial

ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated March 26, 2021 (before its estimated June 30, 2021 completion). Its status may not reflect the trial's current state.
Summary
Open-label, uncontrolled, phase 1-2 study to evaluate the safety, tolerability, pharmacodynamic effects, and preliminary efficacy of ABX196 administered in combination with nivolumab in patients with hepatocellular carcinoma
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2019-03-29; most recent amendment 2026-04-22.
Status change: Recruiting → Completed 2024-05-17
Status change: Not Yet Recruiting → Recruiting 2019-09-25
Trial Details
NCT Number NCT03897543
Lead Sponsor Abivax S.A.
Collaborators: C3 Research Associates
Conditions Carcinoma, Hepatocellular
Enrollment 48 participants
Start Date 2019-08-30
Primary Completion 2021-06-30 (estimated)
Study Completion 2023-06-30 (estimated)
Updated on ClinicalTrials.gov 2021-03-26